ARROWHEAD PHARMACEUTICALS, INC. ARWR
Nasdaq · XNAS · stock · Pharmaceutical Preparations
Chart by TradingView
4/9
Piotroski F — financial health
0.82
Altman Z″ — distress risk · distress
—
Dividend payout · no dividend
Financials (annual, from 10-K)
| FY | Revenue | Net income | Gross profit | Free cash flow | Equity |
|---|---|---|---|---|---|
| 2025 | $829.4M | -$1.6M | — | $156.9M | $503.4M |
| 2024 | $3.6M | -$599.5M | — | -$604.3M | $191.1M |
| 2023 | $240.7M | -$205.3M | — | -$330.6M | $287.2M |
| 2022 | $243.2M | -$176.1M | — | -$188.9M | $418.3M |
| 2021 | $138.3M | -$140.8M | — | $147.7M | $408.8M |
| 2020 | $88.0M | -$84.6M | — | -$107.8M | $461.8M |
Recent insider activity (Form 4)
| Insider | Role | Date | Action | Shares | Price |
|---|---|---|---|---|---|
| Cohen Matthew Gregory | director | 2026-06-15 | Grant | 11,882 | — |
| Lu Hongbo | director | 2026-05-12 | Sell | 2,970 | $76.88 |
| Hamilton James C | Chief Medical Officer | 2026-04-23 | Sell | 10,000 | $75.00 |
| Apel Daniel Joseph | Chief Financial Officer | 2026-04-22 | Sell | 3,208 | $70.11 |
| Apel Daniel Joseph | Chief Financial Officer | 2026-04-22 | Sell | 8,730 | $71.92 |
| Apel Daniel Joseph | Chief Financial Officer | 2026-04-22 | Sell | 1,157 | $70.45 |
| Hamilton James C | Chief Medical Officer | 2026-03-05 | Sell | 10,000 | $64.19 |
| Hamilton James C | Chief Medical Officer | 2026-01-06 | Grant | 75,000 | — |
Why these scores methodology →
Piotroski F-score: 4/9
- Positive return on assets
- Positive operating cash flow
- Rising ROA
- Cash flow exceeds net income
- Lower long-term debt
- Rising current ratio
- No share dilution
- Rising gross margin
- Rising asset turnover
Altman Z″: 0.82 (distress)
- Working capital / assets 0.545
- Retained earnings / assets -1.175
- EBIT / assets 0.071
- Equity / liabilities 0.571
Source: SEC EDGAR filings · CIK 0000879407 · as of 2025-09-30. Figures are facts from filings plus Stocktoria's own computed scores — not investment advice.